loading...| Preferred Name |
Clioquinol |
|
| Synonyms |
5-Chloro-7-iodo-8-hydroxyquinoline Iodochlorohydroxyquinoline 5-Chloro-7-iodo-quinolin-8-ol AI3-16451 CLIOQUINOL Clioquinol Mycoquin |
|
| Definitions |
An orally bioavailable, lipophilic, copper-binding, halogenated 8-hydroxyquinoline with antifungal, antiparasitic and potential antitumor activities. Clioquinol forms a stable chelate with copper (copper (II) ions), which inhibits the chymotrypsin-like activity of the proteasome; consequently, ubiquitinated proteins may accumulate in tumor cells, followed by tumor cell apoptosis and the inhibition of tumor angiogenesis. In addition, the clioquinol-copper complex appears to decrease the expression of androgen receptors (AR) in human copper-enriched prostate cancer cells. Serum levels of copper are often elevated in patients with cancer; copper chelation may inhibit copper-dependent endothelial cell proliferation and tumor secretion of angiogenic factors. |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C65337 |
|
| CAS_Registry |
130-26-7 |
|
| Chemical_Formula |
C9H5ClINO |
|
| code |
C65337 |
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 |
|
| Contributing_Source |
FDA GDC |
|
| DEFINITION |
An orally bioavailable, lipophilic, copper-binding, halogenated 8-hydroxyquinoline with antifungal, antiparasitic and potential antitumor activities. Clioquinol forms a stable chelate with copper (copper (II) ions), which inhibits the chymotrypsin-like activity of the proteasome; consequently, ubiquitinated proteins may accumulate in tumor cells, followed by tumor cell apoptosis and the inhibition of tumor angiogenesis. In addition, the clioquinol-copper complex appears to decrease the expression of androgen receptors (AR) in human copper-enriched prostate cancer cells. Serum levels of copper are often elevated in patients with cancer; copper chelation may inhibit copper-dependent endothelial cell proliferation and tumor secretion of angiogenic factors. |
|
| FDA_UNII_Code |
7BHQ856EJ5 |
|
| FULL_SYN |
5-Chloro-7-iodo-8-hydroxyquinoline Iodochlorohydroxyquinoline 5-Chloro-7-iodo-quinolin-8-ol AI3-16451 CLIOQUINOL Clioquinol Mycoquin |
|
| Is_Value_For_GDC_Property | ||
| label |
Clioquinol |
|
| Legacy Concept Name |
Clioquinol |
|
| Maps_To |
Clioquinol |
|
| NCI_Drug_Dictionary_ID |
653982 |
|
| NSC Number |
3531 |
|
| PDQ_Closed_Trial_Search_ID |
653982 |
|
| PDQ_Open_Trial_Search_ID |
653982 |
|
| Preferred_Name |
Clioquinol |
|
| prefixIRI |
Thesaurus:C65337 |
|
| Semantic_Type |
Pharmacologic Substance |
|
| UMLS_CUI |
C0021978 |
|
| subClassOf |